Insulet class action targets disclosures after 24.02% stock drop, August 31 deadline

A securities class action against Insulet Corporation is focusing on whether the company adequately disclosed alleged manufacturing-control defects during the February 21, 2025 to May 26, 2026 class period. Glancy Prongay Wolke & Rotter LLP said the complaint alleges Insulet failed to disclose defective manufacturing controls and procedures that created a heightened risk its products could violate safety regulations or pose a risk of injury, leaving public statements materially false and misleading. The suit points to two voluntary Medical Device Corrections in 2026 involving Omnipod products. Insulet disclosed on March 12, 2026 that it had initiated a correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through ongoing product monitoring, after which the stock fell $16.23, or 6.9%, to close at $219.84 on March 13. On May 26, 2026, the company disclosed another voluntary Medical Device Correction for specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue that could result in insulin under-delivery; the shares then fell $7.79, or 5.1%, to close at $146.01 on May 27. Earlier case materials also alleged deficiencies tied to the Acton, Massachusetts facility and said the two disclosures left the stock down from $236.07 to $146.01 across the period. A separate notice from Levi & Korsinsky, operating under the SueWallSt brand, similarly says institutional investors should assess losses and potential lead-plaintiff participation before the August 31, 2026 deadline.